Still River Systems Inc. said Wednesday it signed a long-term licensing agreement with the Massachusetts Institute of Technology for technologies to be used with its small-footprint, single-room proton therapy system.
The agreement covers superconducting accelerator technologies developed at MIT's Plasma Science and Fusion Center in collaboration with Still River Systems, the Littleton, Mass.-based company said. Terms of the deal weren't disclosed.
Still River's first synchrotron-based proton therapy unit, called the Monarch 250, is being installed at the Barnes-Jewish Hospital, a 1,228-bed facility in St. Louis. It's expected to start treating patients next year.
Early published figures put the total cost of equipment and construction of Still River's project at around $20 million, well shy of the $120 million to $300 million price tag of most U.S. proton therapy centers.
